CHINA BRIEF | Medical AI startup Shukun closes USD 28.2 million Series B1 round

Written by Song Jingli Published on 

BOC International, the investment bank unit of state-owned Bank of China is one of the investors.

Beijing-based artificial intelligence startup Shukun has raised RMB 200 million (USD 28.2 million) in its Series B1 round led by BOC International, the investment bank unit of state-owned Bank of China, and joined by venture capital firms CCV and Huagai Capital, 36Kr reported on Monday.

New funds will be used to apply Shukun’s AI technologies in diagnosing cardiovascular and neurological diseases, as well as cancer detection, in hospitals across the country, especially in grass-root medical institutions, said the company.

Shukun, which was founded in 2017, rolled out CoronaryDoc, an assisting software to help doctors diagnose heart diseases, leveraging on visual recognition technologies in early 2018, according to the company’s website. By the end of September 2019, CoronaryDoc has been used in more than 100 hospitals in China on a trial basis, the firm added.

In February, Shukun launched an AI system to help diagnose COVID-19, which has been used in a slew of hospitals across China, including the Wuhan Zhongxin Hospital in Hubei’s capital Wuhan, where the pandemic first originated in late January, according to Beijing Daily.

36Kr is KrASIA’s parent company

This article is part of KrASIA’s “China Brief” section, where KrASIA’s reporters will provide quick daily updates about the tech ecosystem in China.


You might like these

  • News

    Baidu to split shares ahead of rumored Hong Kong listing


    Song Jingli

    25 Jan 2021    11:38 AM

KrASIA InsightsKrASIA Insights

  • Beijing-based AI firm Aibee digitizes “space, people, and products” for brick-and-mortar retailers.


    This firm digitizes offline shopping: Inside China’s Startups 

    By Wency Chen

    23 Jan 202101:05 AM

Most PopularMost Popular

See All